Sphingosine-1-Phosphate Recruits Macrophages and Microglia and Induces a Pro-Tumorigenic Phenotype That Favors Glioma Progression.

S1P anti-inflammatory glioblastoma microenvironment tumor-associated macrophages/microglia

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
12 Jan 2023
Historique:
received: 30 11 2022
revised: 05 01 2023
accepted: 10 01 2023
entrez: 21 1 2023
pubmed: 22 1 2023
medline: 22 1 2023
Statut: epublish

Résumé

Glioblastoma is the most aggressive brain tumor in adults. Treatment failure is predominantly caused by its high invasiveness and its ability to induce a supportive microenvironment. As part of this, a major role for tumor-associated macrophages/microglia (TAMs) in glioblastoma development was recognized. Phospholipids are important players in various fundamental biological processes, including tumor-stroma crosstalk, and the bioactive lipid sphingosine-1-phosphate (S1P) has been linked to glioblastoma cell proliferation, invasion, and survival. Despite the urgent need for better therapeutic approaches, novel strategies targeting sphingolipids in glioblastoma are still poorly explored. Here, we showed that higher amounts of S1P secreted by glioma cells are responsible for an active recruitment of TAMs, mediated by S1P receptor (S1PR) signaling through the modulation of Rac1/RhoA. This resulted in increased infiltration of TAMs in the tumor, which, in turn, triggered their pro-tumorigenic phenotype through the inhibition of NFkB-mediated inflammation. Gene set enrichment analyses showed that such an anti-inflammatory microenvironment correlated with shorter survival of glioblastoma patients. Inhibition of S1P restored a pro-inflammatory phenotype in TAMs and resulted in increased survival of tumor-bearing mice. Taken together, our results establish a crucial role for S1P in fine-tuning the crosstalk between glioma and infiltrating TAMs, thus pointing to the S1P-S1PR axis as an attractive target for glioma treatment.

Identifiants

pubmed: 36672428
pii: cancers15020479
doi: 10.3390/cancers15020479
pmc: PMC9856301
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Mol Cell Biol. 2003 Mar;23(5):1534-45
pubmed: 12588974
Cancer Cell. 2017 Mar 13;31(3):326-341
pubmed: 28292436
Trends Mol Med. 2011 Aug;17(8):463-72
pubmed: 21514226
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
Nat Rev Cancer. 2010 Jul;10(7):489-503
pubmed: 20555359
Biochem Biophys Res Commun. 2008 Feb 22;366(4):963-8
pubmed: 18088600
Glia. 2003 Dec;44(3):183-9
pubmed: 14603460
PLoS One. 2011;6(8):e23902
pubmed: 21901144
Neurochem Int. 2016 Mar;94:90-7
pubmed: 26921668
J Pathol. 2008 Sep;216(1):15-24
pubmed: 18553315
J Biol Chem. 2009 Feb 6;284(6):3408-17
pubmed: 19074142
Cancers (Basel). 2020 Jan 01;12(1):
pubmed: 31906280
Mediators Inflamm. 2016;2016:1503206
pubmed: 26884643
Biochem Biophys Res Commun. 2007 Apr 27;356(1):239-44
pubmed: 17349972
Mol Cancer Res. 2013 Jul;11(7):793-807
pubmed: 23615526
Int J Mol Med. 2017 May;39(5):1277-1284
pubmed: 28405684
Pharmacol Ther. 2020 Mar;207:107464
pubmed: 31863815
Acta Neuropathol Commun. 2021 Mar 25;9(1):54
pubmed: 33766119
Neuro Oncol. 2010 Apr;12(4):351-65
pubmed: 20308313
Biomolecules. 2020 Sep 23;10(10):
pubmed: 32977496
Oncol Lett. 2019 Nov;18(5):5374-5382
pubmed: 31620198
Mol Interv. 2010 Oct;10(5):263-70
pubmed: 21045240
Cancer Res. 2003 Sep 15;63(18):5962-9
pubmed: 14522923
Elife. 2018 Feb 21;7:
pubmed: 29465400
Adv Biol Regul. 2020 Jan;75:100670
pubmed: 31708456
J Med Chem. 2004 Dec 30;47(27):6662-5
pubmed: 15615513
FASEB J. 2008 Aug;22(8):2629-38
pubmed: 18362204
Nat Med. 2013 Nov;19(11):1423-37
pubmed: 24202395
Glia. 2011 Aug;59(8):1169-80
pubmed: 21446047
J Biochem Pharmacol Res. 2013 Dec;1(4):197-203
pubmed: 25383272
J Biol Chem. 2013 Dec 27;288(52):37355-64
pubmed: 24265321
Cancer Cell. 2017 Jul 10;32(1):42-56.e6
pubmed: 28697342
Handb Exp Pharmacol. 2020;259:3-17
pubmed: 31321542
Glia. 1997 Nov;21(3):327-31
pubmed: 9383041
Neuro Oncol. 2006 Jul;8(3):261-79
pubmed: 16775224
Neuron. 2014 Apr 16;82(2):380-97
pubmed: 24742461
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Biochem Biophys Res Commun. 2002 Dec 6;299(3):483-7
pubmed: 12445827
Cancer Res. 2019 Aug 15;79(16):4211-4226
pubmed: 31239273
Nat Immunol. 2011 Jun 05;12(7):672-80
pubmed: 21642988
Clin Cancer Res. 2010 Dec 1;16(23):5781-95
pubmed: 21138870
Expert Rev Mol Med. 2007 Oct 15;9(28):1-18
pubmed: 17935635
Nat Commun. 2020 Jan 23;11(1):437
pubmed: 31974367
Curr Drug Targets. 2008 Aug;9(8):662-73
pubmed: 18691013
Nat Neurosci. 2014 Jan;17(1):131-43
pubmed: 24316888
Curr Opin Immunol. 2022 Jun;76:102181
pubmed: 35462276
J Biol Chem. 2000 Jan 7;275(1):271-8
pubmed: 10617615
Stem Cell Rev Rep. 2019 Feb;15(1):139-154
pubmed: 30302660
Biometrics. 2008 Dec;64(4):1263-9
pubmed: 18325074
J Lipid Res. 2014 Aug;55(8):1596-608
pubmed: 24459205
Acta Neuropathol. 2019 Aug;138(2):275-293
pubmed: 31062076
Circ Res. 2008 Apr 25;102(8):950-8
pubmed: 18323526
Cancer Cell. 2013 Sep 9;24(3):331-46
pubmed: 23993863
Mol Biol Cell. 2007 Oct;18(10):3810-9
pubmed: 17652460
Oncotarget. 2016 Mar 15;7(11):13031-46
pubmed: 26887055
Blood. 2012 Aug 16;120(7):1458-65
pubmed: 22745305
Cell. 2020 Sep 3;182(5):1252-1270.e34
pubmed: 32818467
PLoS One. 2012;7(8):e43339
pubmed: 22937035
Mol Cancer Ther. 2009 Apr;8(4):809-20
pubmed: 19372554
Front Immunol. 2015 Jul 22;6:370
pubmed: 26257737
Mol Cell Biol. 2008 Sep;28(18):5687-97
pubmed: 18644866
Mol Cancer Res. 2009 Jan;7(1):23-32
pubmed: 19147534
Mol Cell Biol. 2015 Nov 09;36(2):320-9
pubmed: 26552704
Cell Signal. 2014 Oct;26(10):2249-58
pubmed: 25035231
Nat Med. 2010 Dec;16(12):1421-8
pubmed: 21102457
PeerJ. 2020 May 20;8:e9038
pubmed: 32509446
Front Immunol. 2020 Mar 04;11:178
pubmed: 32194542
Nature. 2010 Jun 24;465(7301):1084-8
pubmed: 20577214
Oncotarget. 2017 Apr 27;8(35):58247-58263
pubmed: 28938552
Mol Pharmacol. 2008 Nov;74(5):1308-18
pubmed: 18708635
Proc Natl Acad Sci U S A. 2016 Mar 22;113(12):E1738-46
pubmed: 26884166
FASEB J. 2011 Jul;25(7):2408-17
pubmed: 21450910
Prog Lipid Res. 2016 Apr;62:93-106
pubmed: 26970273
J Neuropathol Exp Neurol. 2005 Aug;64(8):695-705
pubmed: 16106218
Cell Microbiol. 2018 May;20(5):e12836
pubmed: 29498184
Hematol Oncol Clin North Am. 2012 Aug;26(4):825-53
pubmed: 22794286
Cell Rep. 2016 Nov 22;17(9):2445-2459
pubmed: 27840052
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Future Med Chem. 2012 Apr;4(6):771-81
pubmed: 22530640
Oncol Lett. 2019 Aug;18(2):1259-1266
pubmed: 31423186
Blood. 2006 Sep 1;108(5):1635-42
pubmed: 16690965
Nat Med. 2018 Sep;24(9):1459-1468
pubmed: 30104766
Ann Endocrinol (Paris). 2019 Nov;80(5-6):263-272
pubmed: 31455516
Nat Neurosci. 2006 Dec;9(12):1512-9
pubmed: 17115040
Nucleic Acids Res. 2012 Sep 1;40(17):e133
pubmed: 22638577
Anticancer Res. 2019 Feb;39(2):663-670
pubmed: 30711943

Auteurs

Lavinia Arseni (L)

Division of Molecular Genetics, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.

Rakesh Sharma (R)

Schaller Research Group at the University of Heidelberg and the German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Molecular Mechanisms of Tumor Invasion, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Faculty of Biosciences, Heidelberg University, 69120 Heidelberg, Germany.

Norman Mack (N)

Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, 69120 Heidelberg, Germany.

Deepthi Nagalla (D)

Schaller Research Group at the University of Heidelberg and the German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Molecular Mechanisms of Tumor Invasion, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.

Sibylle Ohl (S)

Division of Molecular Genetics, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.

Thomas Hielscher (T)

Division of Biostatistics, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.

Mahak Singhal (M)

European Center for Angioscience (ECAS), Medical Faculty Mannheim, Heidelberg University, 68167 Mannheim, Germany.
Division of Vascular Oncology and Metastasis, German Cancer Research Center (DKFZ)-ZMBH Alliance, 69120 Heidelberg, Germany.

Robert Pilz (R)

Faculty of Biosciences, Heidelberg University, 69120 Heidelberg, Germany.
Lipid Pathobiochemistry, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.

Hellmut Augustin (H)

European Center for Angioscience (ECAS), Medical Faculty Mannheim, Heidelberg University, 68167 Mannheim, Germany.
Division of Vascular Oncology and Metastasis, German Cancer Research Center (DKFZ)-ZMBH Alliance, 69120 Heidelberg, Germany.

Roger Sandhoff (R)

Lipid Pathobiochemistry, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.

Christel Herold-Mende (C)

Department of Neurosurgery, Division of Experimental Neurosurgery, Heidelberg University Hospital, 69120 Heidelberg, Germany.

Björn Tews (B)

Schaller Research Group at the University of Heidelberg and the German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Molecular Mechanisms of Tumor Invasion, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.

Peter Lichter (P)

Division of Molecular Genetics, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.

Martina Seiffert (M)

Division of Molecular Genetics, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.

Classifications MeSH